Welcome to our dedicated page for Nuwellis news (Ticker: NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.
Nuwellis, Inc. develops and commercializes medical technology for patients with cardiorenal conditions, including Aquadex SmartFlow ultrafiltration therapy for fluid removal in fluid overload. Company news commonly covers financial results, Aquadex software and product updates, patent activity for catheter technology, clinical case studies in pediatric and heart-failure care, medical-meeting participation, commercial territory expansion, and hospital-support initiatives.
Nuwellis (Nasdaq: NUWE) completed a successful FDA pre-submission 510(k) meeting on a proposed Aquadex SmartFlow label expansion for pediatric patients weighing 5 kg and above, versus the current 20 kg threshold.
The FDA provided feedback on a pathway using bench testing, toxicology, and pediatric clinical evidence, and Nuwellis expects to submit by the end of 2026.
Nuwellis (Nasdaq: NUWE) reported Q1 2026 net sales of $2.4 million, a 26% year-over-year increase, with gross margin improving to 70.1%. Operating expenses were about $6.0 million, and net loss attributable to common shareholders was about $4.3 million.
The company completed the Rendiatech acquisition, expanded U.S. commercial coverage, appointed new leadership, received a new U.S. patent, and obtained a patent Notice of Allowance. Nuwellis reported $2.2 million in cash and no debt at March 31, 2026.
Nuwellis (Nasdaq: NUWE) will report first-quarter 2026 financial results for the period ended March 31, 2026, premarket on Tuesday, May 12, 2026. A conference call and webcast will follow at 9:00 AM ET on May 12, 2026 to discuss results and provide a company update.
Investors can access the live webcast on the company Investors page (https://ir.nuwellis.com) or listen by phone at 1-800-274-8461 (U.S.) or 1-203-518-9814 (international) using conference ID NUWEQ1. An audio archive will be available after the call.
Nuwellis (Nasdaq: NUWE) highlighted a University of Iowa case study presented at the 46th ISHLT Annual Meeting (April 22–25, 2026) on pediatric ultrafiltration for chemotherapy‑induced dilated cardiomyopathy with recurrent fluid overload.
The poster evaluated feasibility, safety, and clinical impact of Aquadex ultrafiltration when diuretics failed, and notes the device is indicated for patients ≥20 kg for temporary or extended continuous ultrafiltration under trained provider supervision.
Nuwellis (Nasdaq: NUWE) announced on April 28, 2026 that the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent covering its dual lumen midline catheter for ultrafiltration therapy.
The allowed patent covers separate withdrawal and infusion lumens with pressure‑balancing features and a segmented reinforcement structure that enables bedside length customization while preserving kink resistance and stable flow. According to Nuwellis, the technology is intended to complement the Aquadex SmartFlow® system and support broader access to ultrafiltration in hospital and outpatient settings.
Nuwellis (Nasdaq: NUWE) will participate in the AATS 106th Annual Meeting May 2–5 in Chicago and attend the ERAS Cardiac Spring Retreat. The company will showcase its Aquadex SmartFlow ultrafiltration system for fluid removal at Booth 530 and engage with cardiac surgery thought leaders.
Nuwellis (NASDAQ: NUWE) released a software update for the Aquadex SmartFlow ultrafiltration platform on April 21, 2026. The update reduces ultrafiltration step size from 10 mL/hr to 5 mL/hr, adds a refined blood flow algorithm to reduce nuisance alarms, improves clotting visibility, and expands hourly therapy logs. The update targets improved usability and more precise fluid management for pediatric patients and is available to existing customers at no cost via standard deployment with field support.
Nuwellis (NASDAQ: NUWE) announced the return of three former employees on April 16, 2026: Liby Cielo (Principal Account Manager), Meredith Stein (Senior Clinical Education Specialist), and Scott Campbell (Area Vice President, Sales). The hires aim to accelerate commercial adoption and clinical support for Aquadex therapy across hospital and outpatient settings.
The company emphasized rebuilding commercial and clinical capacity, regional growth in South Texas and the western U.S., expanded clinician education, and support for adult and pediatric fluid‑overload patients following recent reimbursement progress.
Nuwellis (Nasdaq: NUWE) has retained CORE IR for public relations, shareholder communications, and social media management, effective April 9, 2026. CORE IR will drive market awareness, convey Nuwellis' solutions and development plans, and manage digital communications to investors, partners, and key stakeholders.
The engagement aims to support Nuwellis' growth strategy and expand outreach across medical device and diagnostics markets through integrated multi-channel communications.
Nuwellis (Nasdaq: NUWE) announced creation of a dedicated South Texas commercial territory on April 7, 2026 to strengthen hospital engagement and expand access to Aquadex therapy in a region with large hospital systems and leading cardiac and critical care programs.
The focused territory is intended to provide more direct clinical support to physicians and care teams evaluating advanced fluid management strategies, reinforcing Nuwellis’ commercial infrastructure and partnerships with hospitals treating complex cardiorenal patients.